RXST
Rxsight Inc
4.80$
-3.1%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 55.2% | 38.2% | 29.9% | 30.5% | 44.5% | 28.4% | 25.2% | 25.1% | 20.1% | 22.5% | 23.9% | 23.3% | 22.5% | |
| 44.8% | 61.8% | 70.1% | 69.5% | 55.5% | 71.6% | 74.8% | 74.9% | 79.9% | 77.5% | 76.1% | 76.7% | 77.5% | |
| 23.2% | 25.7% | 27.2% | 23.8% | 19.5% | 22.9% | 27.4% | 30.4% | 29.9% | 27.3% | 30.7% | 27.4% | 28.7% | |
| 62.4% | 74.1% | 79.0% | 69.6% | 56.4% | 70.1% | 75.6% | 86.1% | 90.1% | 84.9% | 103.1% | 90.2% | 92.0% | |
| 85.6% | 99.7% | 106.2% | 93.4% | 75.9% | 93.0% | 102.9% | 116.5% | 120.0% | 112.2% | 133.8% | 117.5% | 120.7% | |
| -40.8% | -38.0% | -36.2% | -23.9% | -20.3% | -21.5% | -28.2% | -41.6% | -40.1% | -34.8% | -57.7% | -40.8% | -43.2% | |
| 0.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| -40.4% | -32.2% | -30.8% | -17.4% | -13.9% | -14.7% | -21.6% | -34.9% | -32.3% | -28.0% | -51.4% | -35.6% | -36.7% | |
| 0.0% | -0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.3% | 0.1% | |
| -40.5% | -32.1% | -30.8% | -17.4% | -14.0% | -14.8% | -21.6% | -35.0% | -32.4% | -28.1% | -51.4% | -35.9% | -36.8% | |
| -36.0% | -28.4% | -26.9% | -15.0% | -11.4% | -13.4% | -19.5% | -32.6% | -29.5% | -25.4% | -48.7% | -32.6% | -33.9% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.